Volcano Corporation  

(Public, NASDAQ:VOLC)   Watch this stock  
Find more results for volc
16.26
+0.08 (0.49%)
Real-time:   1:39PM EDT
NASDAQ real-time data - Disclaimer
Currency in USD
Range 16.00 - 16.28
52 week 15.38 - 24.62
Open 16.23
Vol / Avg. 237,334.00/542,846.00
Mkt cap 832.96M
P/E     -
Div/yield     -
EPS -0.79
Shares 51.23M
Beta 0.38
Inst. own 118%
Aug 11, 2014
Volcano Corp Corporate investor Day - 8:30AM EDT - Add to calendar
Aug 7, 2014
Q2 2014 Volcano Corp Earnings Call - 5:00PM EDT - Add to calendar
Aug 7, 2014
Q2 2014 VOLCANO CORPORATION Earnings Release - 4:00PM EDT - Add to calendar
Jun 10, 2014
VOLCANO CORPORATION at Goldman Sachs Healthcare Conference
Jun 5, 2014
VOLCANO CORPORATION iFR Update Conference Call - Webcast
Jun 3, 2014
VOLCANO CORPORATION Annual Shareholder Meeting
May 27, 2014
VOLCANO CORPORATION Announces Agreement To Acquire AtheroMed Conference Call - Webcast
May 13, 2014
VOLCANO CORPORATION at Bank of America Merrill Lynch Health Care Conference
May 2, 2014
Q1 2014 VOLCANO CORPORATION Earnings Conference Call - Webcast
May 2, 2014
Q1 2014 VOLCANO CORPORATION Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '14) 2013
Net profit margin -11.53% -8.76%
Operating margin -9.01% -7.60%
EBITD margin - 5.28%
Return on average assets -5.25% -3.98%
Return on average equity -14.51% -9.74%
Employees 1,800 -
CDP Score - -

Address

SUITE 500, 3721 VALLEY CENTRE DRIVE
SAN DIEGO, CA 92130
United States - Map
+1-800-2284728 (Phone)
+1-858-7200325 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Volcano Corporation (Volcano) designs, develops, manufactures and commercializes a range of precision guided therapy tools, including intravascular ultrasound (IVUS), and fractional flow reserve (FFR), products. The Company is facilitating the adoption of functional percutaneous interventional (PCI), in which its FFR technology is used to determine whether or not a stent is necessary, and IVUS is used to guide stent placement and optimization. It markets its products to physicians and technicians who perform PCI procedures in hospitals and to other personnel who make purchasing decisions on behalf of hospitals. Its products consist of multi-modality consoles, which are marketed as stand-alone units or as customized units that can be integrated into a range of hospital-based interventional surgical suites called catheterization laboratories (cath labs). In June 2014, Volcano Corp acquired the entire share capital of AtheroMed Inc.

Officers and directors

Ronald A. Matricaria Chairman of the Board, Lead Independent Director
Bio & Compensation  - Reuters
R. Scott Huennekens President, Chief Executive Officer, Director
Age: 50
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
John T. Dahldorf Chief Financial Officer
Age: 57
Bio & Compensation  - Reuters
Michele Perrino President, Europe, Africa, Middle East, and India Operations
Age: 43
Bio & Compensation  - Reuters
Darin M. Lippoldt Executive Vice President, Chief Compliance Officer, General Counsel, Secretary
Age: 48
Bio & Compensation  - Reuters
John Onopchenko Executive Vice President - Strategy, Business Development and Integrations
Age: 55
Bio & Compensation  - Reuters
Daniel J. Wolterman Director
Age: 57
Bio & Compensation  - Reuters
Kieran T. Gallahue Independent Director
Age: 50
Bio & Compensation  - Reuters
Lesley H. Howe Independent Director
Age: 69
Bio & Compensation  - Reuters
Siddhartha Kadia Ph.D. Independent Director
Age: 44
Bio & Compensation  - Reuters